Lista de obras - Laura Mezquita - Dominio Público Uruguay

Acneiforme rash in woman with pulmonary adenocarcinoma

artículo científico publicado en 2008

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer

artículo científico publicado en 2019

Acrometastasis as the initial presentation of lung adenocarcinoma in a young woman.

artículo científico publicado en 2015

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases

artículo científico publicado en 2019

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

artículo científico publicado en 2020

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

artículo científico publicado en 2018

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

scientific article published on 10 August 2020

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

artículo científico publicado en 2019

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

scientific article published on 21 November 2019

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome

artículo científico publicado en 2020

CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

artículo científico publicado en 2020

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

artículo científico publicado en 2020

Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy

scientific article published on 04 September 2020

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

scientific article published on 13 December 2019

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients

scientific article published on 14 January 2019

Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients

artículo científico publicado en 2020

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer

artículo científico publicado en 2020

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer

scientific article published on 02 April 2020

Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer

scientific article published on 01 August 2020

Congenital Bronchial Artery to Pulmonary Artery Fistula in a Patient With Lung Cancer Involving the Carina

artículo científico publicado en 2016

Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer

artículo científico publicado en 2020

Correction: C797S, T790M and sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR

artículo científico publicado en 2019

Development of thyroid carcinoma during treatment with pembrolizumab in a lung cancer patient

scientific article published on 14 December 2019

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

scientific article published on 04 October 2019

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

scientific article published on 01 January 2019

Durvalumab for the treatment of non-small cell lung cancer

artículo científico publicado en 2018

Durvalumab in non-small-cell lung cancer patients: current developments.

artículo científico publicado en 2017

Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

artículo científico publicado en 2016

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

artículo científico publicado en 2020

Focus on Recommendations for the Management of Non-small Cell Lung Cancer

artículo científico publicado en 2019

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

artículo científico publicado en 2017

Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC

scientific article published on 11 July 2019

Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations

scientific article published on 18 May 2020

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

scientific article published on 01 November 2018

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients

artículo científico publicado en 2020

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

artículo científico publicado en 2019

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations

scientific article published on 13 March 2020

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

artículo científico publicado en 2018

Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

artículo científico publicado en 2017

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

scientific article published on 20 August 2018

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

scientific article published on 30 September 2020

Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies

artículo científico publicado en 2020

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients

scientific article published on 03 May 2019

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

artículo científico publicado en 2020

Letter to the Editor about Sorich et al

artículo científico publicado en 2019

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer

artículo científico publicado en 2020

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

scientific article published in PLoS ONE

Nivolumab-induced pneumonitis complicated by cyst formation

artículo científico publicado en 2018

Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?

scientific article published on 30 July 2019

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

artículo científico publicado en 2020

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

scientific article published on 16 February 2019

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

artículo científico publicado en 2020

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients

artículo científico publicado en 2017

Progress in the Management of Advanced Thoracic Malignancies in 2017.

artículo científico publicado en 2018

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients

artículo científico publicado en 2018

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients

artículo científico publicado en 2020

Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab

artículo científico publicado en 2018

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2019

Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing

artículo científico publicado en 2019

Safety of osimertinib in EGFR-mutated non-small cell lung cancer

scientific article published on 05 December 2018

Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.

artículo científico publicado en 2016

Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer

artículo científico publicado en 2020

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors

scientific article published on 13 June 2019

The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors

scientific article published on 27 February 2020

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients

scientific article published on 01 August 2020

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

artículo científico publicado en 2018

Unusual progressive neurological syndrome in epidermal growth factor receptor-mutated lung adenocarcinoma, diagnosed at autopsy as invasive meningeal carcinomatosis.

artículo científico publicado en 2016

Lista de obras de Laura Mezquita

Acneiforme rash in woman with pulmonary adenocarcinoma

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer

Acrometastasis as the initial presentation of lung adenocarcinoma in a young woman.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome

CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients

Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer

Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer

Congenital Bronchial Artery to Pulmonary Artery Fistula in a Patient With Lung Cancer Involving the Carina

Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer

Correction: C797S, T790M and sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR

Development of thyroid carcinoma during treatment with pembrolizumab in a lung cancer patient

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

Durvalumab for the treatment of non-small cell lung cancer

Durvalumab in non-small-cell lung cancer patients: current developments.

Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Focus on Recommendations for the Management of Non-small Cell Lung Cancer

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC

Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations

Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Letter to the Editor about Sorich et al

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

Nivolumab-induced pneumonitis complicated by cyst formation

Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients

Progress in the Management of Advanced Thoracic Malignancies in 2017.

Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients

Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer

Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing

Safety of osimertinib in EGFR-mutated non-small cell lung cancer

Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.

Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors

The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors

The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients

The role of brigatinib in crizotinib-resistant non-small cell lung cancer.

Unusual progressive neurological syndrome in epidermal growth factor receptor-mutated lung adenocarcinoma, diagnosed at autopsy as invasive meningeal carcinomatosis.